(1-chloroformyloxy)ethyl 2-pyridinyl disulfide | 892402-96-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (1-chloroformyloxy)ethyl 2-pyridinyl disulfide
• 英文别名: 2-(pyridin-2-yldisulfanyl)ethyl carbonochloridate
• CAS: 892402-96-9
• 化学式: C₈H₈ClNO₂S₂
• 分子量: 249.742
• InChiKey: LDKUPCIUFTUUCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  89.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (1-chloroformyloxy)ethyl 2-pyridinyl disulfide 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 2-((1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-5,9-dioxo-4-oxa-17-aza-bicyclo[14.1.0]heptadecan-17-yl)ethyl 2-(2-(pyridin-2-yl)disulfanyl)ethyl carbonate
  参考文献：
  名称：

  AZIRIDINYL-EPOTHILONE COMPOUNDS

  摘要：

  本发明涉及如下所述的吲哚环毒毒素化合物，以及/或其在下式中具有以下结构的药学上可接受的盐和/或溶剂：其中K为—O—、—S—或—NR7—；A为—(CR8R9)—(CH2)m-Z-，其中Z为—(CHR10)—、—C(═O)—、—C(═O)—C(═O)—、—OC(═O)—、—N(R11)C(═O)—、—SO2—或—N(R11)SO2—；B1为羟基或氰基，R1为氢或B1和R1一起形成双键；R2、R3和R5独立地为氢、烷基、取代烷基、芳基或取代芳基；或R2和R3可以与它们连接的碳一起形成可选择取代的环烷基；R4为氢、烷基、烯烃基、取代烷基、取代烯烃基、芳基或取代芳基；R6为氢、烷基或取代烷基；R7、R8、R9、R10、R11和R12独立地为氢、烷基、取代烷基、环烷基、取代环烷基、芳基、取代芳基、杂环烷基、取代杂环烷基、杂芳基或取代杂芳基；而R13为芳基、取代芳基、杂芳基或取代杂芳基。

  公开号：

  US20070276018A1
• 作为产物：
  描述：

  2,2'-二硫二吡啶 在 吡啶 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.5h， 生成 (1-chloroformyloxy)ethyl 2-pyridinyl disulfide
  参考文献：
  名称：

  Releasable Luciferin−Transporter Conjugates:  Tools for the Real-Time Analysis of Cellular Uptake and Release

  摘要：

  The design, synthesis, and evaluation of conjugates of arginine-rich transporters and luciferin are described that release luciferin only after entry into cells that are stably transfected with luciferase. Each molecule of free luciferin that is released after entry generates a photon that can be measured allowing for real-time quantification of uptake and release in cells. The process provides a method to assay uptake and release of free luciferin as a function of variations in the releasable linker and in the transporter.

  DOI：

  10.1021/ja0586283

文献信息

• [EN] POLYGLYOXYLATES, MANUFACTURE AND USE THEREOF<br/>[FR] POLYGLYOXYLATES, LEUR PRODUCTION ET LEUR UTILISATION
  申请人：UNIV WESTERN ONTARIO

  公开号：WO2015168809A1

  公开（公告）日：2015-11-12

  Self-immolative polymers degrade by an end-to-end depolymerisation mechanism in response to the cleavage of a stabilizing end-cap from the polymer terminus. Examples include homopolymers, mixed polymers including block copolymers, suitable for a variety of applications. A polyglyoxylate can be end-capped or capped with a linker as in a block copolymer.

  自焚式聚合物通过从聚合物末端切割稳定端盖，以端到端解聚机制进行降解。例如包括均聚物、混合聚合物包括区块共聚物，适用于各种应用。聚乙二醇酸可以端接或与连接剂如区块共聚物一样封端。
• [EN] PBD CONJUGATES FOR TREATING DISEASES<br/>[FR] CONJUGUÉS DE PBD POUR LE TRAITEMENT DE MALADIES
  申请人：ENDOCYTE INC

  公开号：WO2017172930A1

  公开（公告）日：2017-10-05

  The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.

  本公开涉及吡咯并苯二氮卓（PBD）前药及其共轭物。本公开还涉及所述共轭物的药物组合物，以及制造和使用它们的方法。
• [EN] CONJUGATES AND COMPOSITIONS FOR DRUG DELIVERY<br/>[FR] CONJUGUÉS ET COMPOSITIONS POUR UNE ADMINISTRATION MÉDICAMENTEUSE
  申请人：BRIGHTGENE BIO MEDICAL TECHNOLOGY CO LTD

  公开号：WO2015106599A1

  公开（公告）日：2015-07-23

  The present invention provides folate receptor binding ligand‐drug delivery conjugates having the formula (F) nL1L2D. The conjugates have high affinity to folate receptor‐positive tumor cells and low toxicity for normal cells. The present invention also relates to preparation methods for such conjugates, pharmaceutical compositions comprising such conjugates, and use of such conjugates for preparing anti‐tumor medicaments.

  本发明提供了具有公式（F）nL1L2D的叶酸受体结合配体-药物传递共轭物。这些共轭物对叶酸受体阳性肿瘤细胞具有高亲和力，对正常细胞毒性低。本发明还涉及这些共轭物的制备方法、包含这些共轭物的药物组合物，以及利用这些共轭物制备抗肿瘤药物的用途。
• Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides
  作者：Iontcho R. Vlahov、Yu Wang、Paul J. Kleindl、Christopher P. Leamon

  DOI：10.1016/j.bmcl.2008.07.041

  日期：2008.8

  Efficient syntheses of folate conjugates of tubulysins and their hydrazides 1a-d are described. These water soluble folate receptor (FR) targeted conjugates are derivatives of folic acid and the potent cytotoxic agents: tubulysin A, B, or their respective hydrazides, connected in regioselective manner via a hydrophilic peptide spacer and a reducible disulfide linker.

  描述了微管溶素及其酰肼1a-d的叶酸共轭物的有效合成。这些水溶性叶酸受体（FR）靶向缀合物是叶酸和有效的细胞毒性剂的衍生物：微管溶素A，B或它们各自的酰肼，通过亲水性肽间隔基和可还原的二硫键接头以区域选择性方式连接。
• CONJUGATES OF AZIRIDINYL-EPOTHILONE ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
  申请人：Vite D. Gregory

  公开号：US20070275904A1

  公开（公告）日：2007-11-29

  The present invention is directed to conjugated compounds comprising a folate, or an analog or derivative thereof, and an aziridinyl epothilone analog, as further described herein, and/or pharmaceutically-acceptable salts and/or solvates thereof, useful in the treatment of cancer or other folate-receptor associated conditions.

  本发明涉及包含叶酸、叶酸类似物或衍生物以及环氧紫杉烷类似物的共轭化合物，如下文进一步描述，并/或其药用可接受盐和/或溶剂，用于治疗癌症或其他叶酸受体相关疾病。